News & Updates

Show Multimedia Only
Durvalumab plus FLOT improves event-free survival in gastric, GEJ adenocarcinoma
Durvalumab plus FLOT improves event-free survival in gastric, GEJ adenocarcinoma
04 Sep 2025 byStephen Padilla

Patients with resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma demonstrate significant improvements in event-free survival (EFS) following treatment with durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy compared with placebo plus FLOT, as shown by the results of the phase III MATTERHORN study.

Durvalumab plus FLOT improves event-free survival in gastric, GEJ adenocarcinoma
04 Sep 2025